New Delhi, March 31 Pharma major Lupin Ltd announced on Tuesday that it has received tentative approval from the US health regulator for its generic version of Sugammadex injection, used for reversing the effects of muscle relaxants administered during surgery.The tentative approval by the US...
New Delhi, March 17 Zydus Lifesciences announced on Tuesday that it has entered into a licensing and supply agreement with Lupin to expand access to the diabetes treatment drug Semaglutide Injection (15 mg/3 ml) with a patient-friendly, reusable pen device in India.The agreement aims to...
New Delhi, February 27 Drug maker Lupin announced on Friday that it has received an Establishment Inspection Report (EIR) from the US health regulator for its manufacturing facility in Goa.The company stated that it has received the EIR with a satisfactory Voluntary Action Indicated (VAI)...
New Delhi, February 25 Drug firm Lupin announced on Wednesday that it has received approval from the US health regulator to market a generic medication to treat seizures.The Mumbai-based firm has received approval from the USFDA for its abbreviated new drug application (ANDA) for Brivaracetam...
anda
brivaracetam
briviact
bse
drug approval
generic medication
india
lupin
oral solution
pharmaceutical industry
pharmaceutical sales
seizures
us market
usfda
New Delhi, February 23 Drug maker Lupin announced on Monday that it has received approval from the European Commission for its biosimilar for the treatment of various eye conditions.The company has received approval for Ranluspec (ranibizumab), following the recent positive opinion from the...
New Delhi, February 16 Drug firm Lupin announced on Monday that it has signed a licensing and supply agreement with Spektus Pharma to commercialize the novel antidepressant DeslaFlex in Canada.The strategic partnership combines Lupin's strong commercial presence in Canada and Spektus's...